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SUMMARY
Background
Opioid-induced constipation (OIC) is a common adverse effect of opioid
therapy.
Aim
To evaluate the long-term safety and tolerability of naloxegol, an oral,
peripherally acting l-opioid receptor antagonist (PAMORA), in patients
with noncancer pain and OIC.
Methods
A 52-week, multicenter, open-label, randomised, parallel-group phase 3
study was conducted in out-patients taking 30–1000 morphine-equivalent
units per day for ≥4 weeks. Patients were randomised 2:1 to receive naloxe-
gol 25 mg/day or usual-care (UC; investigator-chosen laxative regimen)
treatment for OIC.
Results
The safety set comprised 804 patients (naloxegol, n = 534; UC, n = 270).
Mean exposure duration was 268 days with naloxegol and 297 days with
UC. Frequency of adverse events (AEs) was 81.8% with naloxegol and 72.2%
with UC. Treatment-emergent AEs occurring more frequently for naloxegol
vs. UC were abdominal pain (17.8% vs. 3.3%), diarrhoea (12.9% vs. 5.9%),
nausea (9.4% vs. 4.1%), headache (9.0% vs. 4.8%), ﬂatulence (6.9% vs. 1.1%)
and upper abdominal pain (5.1% vs. 1.1%). Most naloxegol-emergent gastro-
intestinal AEs occurred early, resolving during or after naloxegol discontinu-
ation and were mild or moderate in severity; 11 patients discontinued due
to diarrhoea and nine patients owing to abdominal pain. Pain scores and
mean daily opioid doses remained stable throughout the study; no attribut-
able opioid withdrawal AEs were observed. Two patients in each group had
an adjudicated major adverse cardiovascular event unrelated to study drug;
no AEs were reported nor adjudicated as bowel perforations.
Conclusion
In patients with noncancer pain and opioid-induced constipation, naloxegol
25 mg/day up to 52 weeks was generally safe and well tolerated.
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INTRODUCTION
Opioid-induced constipation (OIC) is a very common
adverse effect of opioid therapy1, 2 and is considered by
patients as the most bothersome.1 Stimulation of l-opi-
oid receptors in the gastrointestinal (GI) tract leads to
impaired GI transit and motility with decreased secre-
tions, commonly leading to constipation.2–4 Given the
increase in prevalence of long-term use of opioid medi-
cations in patients with noncancer pain,5 the manage-
ment of OIC in this patient population has become a
major therapeutic challenge.
Treatment of OIC typically employs conservative
approaches, including increased ﬂuid, ﬁbre and exercise2, 4
in conjunction with laxative use2, 4, 6 to facilitate bowel
movements (BMs). However, data on the usefulness of
nonpharmacological strategies are limited.7 Further, the
use of laxatives as a treatment for OIC is hampered by a
lack of placebo-controlled trials deﬁnitively demonstrating
robust efﬁcacy and tolerability.8 Lubiprostone is a US
Food and Drug Administration (FDA)-approved pharma-
cotherapy that acts via a non-opioid receptor mechanism
to alleviate OIC in patients with noncancer pain.9 Lubi-
prostone works by activation of chloride channels in the
intestine to facilitate stool movement.9 Although methyln-
altrexone is also an FDA-approved option for the treat-
ment of OIC, this agent is only available as a subcutaneous
formulation and is exclusively indicated for patients with
advanced medical illness.6
Naloxegol is a novel, oral, peripherally acting l-opioid
receptor antagonist (PAMORA) in clinical development
as a targeted therapy for treatment of the underlying
cause of OIC. Naloxegol is a PEGylated derivative of nal-
oxone, a l-opioid receptor antagonist. PEGylation con-
fers increased oral bioavailability and peripheral
selectivity to the naloxone moiety by a reduction in pas-
sive permeability across the blood-brain barrier. Naloxe-
gol is also a substrate of the P-glycoprotein (PGP)
transporter, which promotes efﬂux of naloxegol and
serves to further restrict its entry into the central ner-
vous system. The efﬁcacy of naloxegol in patients with
OIC and noncancer pain was demonstrated in two repli-
cate double-blind, randomised, placebo-controlled phase
3 trials, each over 12 weeks.10 In both studies, naloxegol
25 mg was associated with statistically signiﬁcant
improvements in stool frequency and numerical
improvements in OIC symptoms compared with placebo,
as assessed by response rate in the overall population
over 12 weeks and in a subgroup of patients with inade-
quate response to laxatives. Furthermore, naloxegol
25 mg signiﬁcantly improved time to ﬁrst post-dose
spontaneous bowel movement (SBM), and days per week
with an SBM (end point deﬁned to assess regularity).
The primary objective of this study was to evaluate
the long-term safety and tolerability of naloxegol 25 mg
in patients with OIC and noncancer pain. The secondary
objective was to compare the long-term safety and toler-
ability of naloxegol 25 mg to that of an investiga-
tor-managed regimen of laxatives (usual care).
METHODS
Study design and patients
This was a phase 3, 52-week, multicentre, open-label,
randomised, parallel-group, safety and tolerability study
(KODIAC-08, NCT01336205), conducted from April 18,
2011, to December 3, 2012, in the US. Eligible patients
aged ≥18 to <85 years were enrolled as new patients
without prior naloxegol treatment after screening and
conﬁrmation of OIC, or as rollover patients from either
the 12-week KODIAC-05 study (NCT01323790) or the
3-month safety extension of the 12-week KODIAC-04
study (NCT01395524). All patients were receiving a sta-
ble maintenance opioid therapy at a dose of 30–1000
morphine-equivalent units (MEUs) per day for noncan-
cer pain. Before randomisation (in the parent study for
rollover patients), OIC was conﬁrmed over a 2-week per-
iod and deﬁned as <3 SBMs per week on average with
≥1 of the following symptoms in ≥25% of BMs: Bristol
stool scale stool type 1 or 2; moderate, severe or very
severe straining; or incomplete BM. Patients who had 0
BMs or an uneven distribution of SBMs (0 SBMs in
1 week with ≥4 SBMs in the other week) over the
2-week OIC conﬁrmation period were not randomised.
During conﬁrmation of OIC, laxative use (other than
rescue medication) was not permitted.
Exclusion criteria included conditions associated with
diarrhoea, intermittent loose stools, or constipation not
related to opioid use that could confound the interpreta-
tion of results; conditions associated with potential
impairment of the structural integrity of the GI tract,
including surgery on the colon or abdomen within
60 days of screening; acute GI conditions imposing risk
to the patient (e.g. acute faecal impaction/complete obsti-
pation, acute surgical abdomen, suspicious abdominal or
rectal examination results) or inadequate response to
laxative rescue during OIC conﬁrmation; treatment with
opioids for cancer-related pain, or history of cancer
within 5 years of screening (except for basal cell or
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squamous cell skin cancer); conditions associated with
increased permeability of the blood-brain barrier (e.g.
multiple sclerosis); increased risk for ventricular arrhyth-
mia; use of mixed opioid agonist/antagonists, opioid
antagonists, or products containing naloxone or naltrex-
one; and use of strong cytochrome P450 3A4 or PGP
inhibitors. Laxatives were prohibited for patients in the
naloxegol arm. However, use of bisacodyl as a rescue
medication (10–15 mg for a total of three doses sepa-
rated by 12-h intervals) was permitted when 72 h had
passed without a BM.
Patients were randomised 2:1 to open-label naloxegol
25 mg once daily or usual-care treatment, using an inter-
nal computer-generated randomisation scheme. In
patients receiving usual care, the treatment regimen was
selected and prescribed as the investigator would typi-
cally do and in accordance with his or her clinical expe-
rience, using laxatives available for use in constipation or
OIC, including those that the patient may already have
been using prior to the study. Patients randomised to
usual-care treatment were not permitted to use any med-
ication for their constipation other than the investiga-
tor-approved medication; any change in laxatives
required the prior agreement of the investigator.
Usual-care treatment consisted of a laxative regimen
chosen by the investigator from a broad range of laxa-
tives; however, peripheral l-opioid antagonists such as
methylnaltrexone or naloxone-containing products were
not permitted. The treatment regimen could be modiﬁed
by the investigator at any point during the 52-week
study period. Lastly, no speciﬁc rescue protocol was
determined for patients randomised to receive usual care.
Patients randomised to naloxegol were required to stop
all other laxatives or bowel regimens during the treat-
ment period but were permitted to use the rescue medi-
cation bisacodyl as previously described.
This study was performed in accordance with the
Declaration of Helsinki and the International Conference
on Harmonisation (ICH)/Good Clinical Practice, applica-
ble regulatory requirements, and the AstraZeneca policy
on Bioethics. The study protocol and informed consent
form was approved by an ethics committee/institutional
review board. All patients provided written informed
consent before any study procedures were conducted.
Assessments
Safety and tolerability were assessed by the incidence,
nature, intensity and relatedness to treatment of all
adverse events (AEs); AEs leading to study discontinua-
tion; AEs of special interest; and signiﬁcant changes in
health status as determined by laboratory and clinical
assessments, vital signs, electrocardiograms (ECGs) and
physical examination. AEs were collated by investigator
query and patient self-report, and recorded by the inves-
tigator using electronic case report forms at the OIC
conﬁrmation visit, baseline, weeks 1 and 2 of treatment,
every month up to 12 months, and at the follow-up visit
(2 weeks after the month 12 visit). Vital signs and labo-
ratory, clinical, and ECG assessments were performed at
screening, baseline, weeks 1 and 2, months 1, 3, 6, 9, 12,
and follow-up. Physical examinations were conducted at
screening, baseline and months 6 and 12. Treat-
ment-emergent AEs were deﬁned as those occurring dur-
ing the treatment period. AEs of special interest included
selected cardiovascular events [major adverse cardiovas-
cular events (MACE, deﬁned as cardiovascular death,
myocardial infarction, stroke), congestive heart failure],
AEs with a potential relationship to blood pressure
changes or opioid withdrawal, and serious GI events
adjudicated for bowel perforation. Serious GI AEs and
cardiovascular AEs were independently and prospectively
adjudicated by separate external committees to identify
any cases of bowel perforation or MACE, respectively.
The effect of treatment on opioid requirements and
pain management was assessed by the following: change
from baseline in the mean daily opioid dose from ran-
domisation to month 1, months 1 to 3, months 3 to 6,
months 6 to 9 and months 9 to 12; change from baseline
in the Numeric Rating Scale (NRS) for pain (0 = no pain;
10 = worst possible pain)11 for weeks 1 and 2 and months
1, 2, 3, 6, 9 and 12; and observed values and change from
baseline in composite score of the modiﬁed Himmelsbach
Opioid Withdrawal Scale (mHOWS)12, 13 to assess
centrally mediated opioid withdrawal symptoms at 2 h
following the ﬁrst dose, week 1, and months 1, 3, 6, 9 and
12. The mHOWS rates yawning, lacrimation, rhinorrhea,
perspiration, tremor, mydriasis, piloerection and restless-
ness on a scale from 0 (none) to 3 (severe).12 Patients were
asked to rate their average pain over the past week on the
NRS at study visits. In addition, the mean bisacodyl dose
per week for naloxegol-treated patients was assessed from
randomisation to month 1, months 1 to 3, months 3 to 6,
months 6 to 9 and months 9 to 12.
Analysis
Baseline data for patients recruited from previous studies
were summarised as of entry into those studies. Safety
analysis was performed using descriptive statistics and
was based on the safety-analysis set (randomised patients
who received ≥1 dose of study drug or usual care). A
Aliment Pharmacol Ther 2014; 40: 771-779 773
ª 2014 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd
Randomised clinical trial: naloxegol safety in opioid-induced constipation
formal calculation of sample size was not performed.
Determination of sample size was based on ICH expo-
sure requirements,14 with the goal of having ≥300 and
≥100 patients complete 6 and 12 months of exposure,
respectively. Randomisation of patients was adjusted as
necessary to meet these requirements.
RESULTS
Demographical and disease characteristics
Of the 844 patients who were randomised, 760 (90%)
were new patients and 84 (10%) participated in previous
naloxegol studies (i.e. rollover patients; Figure 1). The
safety-analysis set consisted of 534 patients in the nal-
oxegol 25-mg arm and 270 patients in the usual-care
arm. Completion rates were 58.1% in the naloxegol
group and 67.3% in the usual-care group.
Patients were predominantly white, with a mean age
of 52.7 years (Table 1). Pain history and baseline total
daily opioid dose and history were similar between treat-
ment groups for newly randomised patients (Table 2).
Use of maintenance opioid medications in patients
from the safety-analysis set is summarised in Table 3.
Distribution of maintenance opioid medications was sim-
ilar between treatment groups. The most commonly used
opioid medications were hydrocodone + acetaminophen
(32.3%), morphine (27.9%), oxycodone (25.0%), oxyco-
done + acetaminophen (18.9%) and tramadol (13.6%).
Use of breakthrough opioid medications (those taken by
the patient from treatment initiation to study completion
or discontinuation) was also assessed. Overall usage of
breakthrough opioid medications was balanced between
treatment groups (naloxegol, 36.0%; usual care, 34.8%).
The most commonly used breakthrough medications
were hydrocodone + acetaminophen (9.8%), oxycodone
(9.6%) and oxycodone + acetaminophen (8.0%).
In the 2 weeks before screening, 66.8% of patients had
taken a laxative. The laxative classes used were balanced
between the treatment groups, with stimulants (54.4%),
stool softeners (30.5%) and polyethylene glycol (14.7%) as
the most commonly used laxatives. Most patients (72.4%)
were taking only one laxative class before screening.
At the start of the study, musculoskeletal and connec-
tive tissue disorders were present in 87.4% of patients
and primarily consisted of back pain (52.9%), osteoar-
thritis (23.3%) and muscle spasms (17.2%). Psychiatric
disorders were also prevalent, occurring in 60.9% of
patients, with insomnia (34.7%), depression (34.2%) and
Enrolled
(N = 2393)
Randomised
(n = 844)
Naloxegol 25 mg/day
(n = 563)*,†
Completed study
(n = 327)
Completed study
(n =189)
Usual care
(n = 281)†
New patients (n = 2309)
Rollover patients (n = 84)
New patients (n = 760)
Rollover patients (n = 84)
New patients (n = 250)
Rollover patients (n = 31)
New patients (n = 510)
Rollover patients (n = 53)
Study discontinuations (n = 207)
Patient decision (n = 70)
Eligibility criteria not fulfilled (n = 9)
Death (n =1)
Adverse event (n = 56)
Severe noncompliance with protocol (n = 8)
Lack of therapeutic effect (n = 4)
Study-specific withdrawal criteria (n = 14)
Lost to follow-up (n = 36)
Other (n = 9)
Study discontinuations (n = 81)
Patient decision (n = 38)
Eligibility criteria not fulfilled (n = 5)
Death (n = 1)
Adverse event (n = 5)
Severe noncompliance with protocol (n = 2)
Study-specific withdrawal criteria (n = 7)
Lost to follow-up (n = 19)
Other (n = 4)
Figure 1 | Patient disposition. *Four patients randomised to naloxegol did not receive study treatment because of
patient decision (n = 2) and did not fulﬁll eligibility criteria (n = 2). †Thirty-six patients (naloxegol 25 mg, n = 25;
usual care, n = 11) who previously or concurrently participated in the naloxegol programme at another study centre or
randomised at two sites where data integrity issues were identiﬁed were excluded from the safety-analysis set and
were not included in the numbers of patients completing or discontinuing the study.
774 Aliment Pharmacol Ther 2014; 40: 771-779
ª 2014 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd
L. Webster et al.
anxiety (27.0%) being the most common conditions.
Gastroesophageal reﬂux disease was reported by 29.5%
of patients. Primary reasons for pain were back pain
(55.9%), ‘other’ (21.1%, mainly localised musculoskeletal
pain) and arthritis (8.5%). Nearly all patients (98.3%)
were taking other medications (in addition to opioids)
during treatment. Benzodiazepine derivatives (41.4%),
other antidepressants (31.1%) and 3-hydroxy-
3-methyl-glutaryl coenzyme A reductase inhibitors
(30.5%) were the most commonly used medication
classes. Medications used by ≥10% of patients were
gabapentin (20.5%), ibuprofen (16.8%), aspirin (15.3%),
alprazolam (15.3%), lisinopril (15.2%), omeprazole
(14.9%), simvastatin (14.6%), vitamins (13.1%), duloxe-
tine hydrochloride (12.6%), carisoprodol (12.1%), zolpi-
dem tartrate (10.4%) and hydrochlorothiazide (10.2%).
Exposure to medication
Mean (s.d.) duration of exposure was 268.1 (136.5)
days with naloxegol and 296.7 (120.8) days with usual
care. In the usual-care arm, 213 (79%) patients took
laxatives at the start of the study, and 197 (73%) did
not change their laxative medication during the study,
including 25 (9%) patients who did not start or take
any laxative medication. Laxatives used in >10% of
usual-care patients were bisacodyl (n = 102, 38%),
macrogol (n = 38, 14.1%) and docusate sodium
(n = 27, 10%).
Table 1 | Patient baseline characteristics (safety-
analysis set)*
Characteristic
Naloxegol 25 mg
(n = 534)
Usual care
(n = 270)
Mean (s.d.) age (years) 52.8 (10.1) 52.7 (10.2)
Age category, n (%)
<50 years 179 (33.5) 96 (35.6)
≥50 to <65 years 302 (56.6) 137 (50.7)
≥65 years 53 (9.9) 37 (13.7)
Women, n (%) 353 (66.1) 179 (66.3)
Race, n (%)
White 423 (79.2) 204 (75.6)
Black 98 (18.4) 60 (22.2)
Asian 4 (0.7) 3 (1.1)
American Indian or
Alaska Native
4 (0.7) 1 (0.4)
Other 5 (0.9) 2 (0.7)
* Data for rollover patients were pre-treatment values from
the respective pivotal 12-week studies (KODIAC-04 and KODI-
AC-05).
Table 2 | Pain history and baseline opioid use (new
patients)
Characteristic
Naloxegol 25 mg
(n = 481)
Usual care
(n = 240)
Primary reason for pain, n (%)*
Back pain 272 (56.5) 131 (54.6)
Arthritis 39 (8.1) 22 (9.2)
Fibromyalgia 33 (6.9) 14 (5.8)
Joint pain 20 (4.2) 15 (6.3)
Other† 117 (24.3) 57 (23.8)
Mean (s.d.) opioid use
Duration of current
use, months
47.8 (49.1) 49.5 (53.3)
Lifetime use (months) 101.0 (89.3) 102.3 (86.0)
Daily dose (mg/day) 151.5 (253.8) 136.7 (138.5)
* Percentage data based on the number of patients in the
safety-analysis set in each treatment group and patient group.
† Includes headache/migraine, neuralgia, pain syndrome and
other conditions such as localised musculoskeletal pain.
Table 3 | Maintenance opioid medications during
treatment (safety-analysis set)*
Opioid Class/Drug,
n (%)†
Naloxegol 25 mg
(n = 534)
Usual care
(n = 270)
Natural opium alkaloids 482 (90.3) 247 (91.5)
Hydrocodone +
acetaminophen
176 (33.0) 84 (31.1)
Morphine 157 (29.4) 67 (24.8)
Oxycodone 126 (23.6) 75 (27.8)
Oxycodone +
acetaminophen
101 (18.9) 51 (18.9)
Hydromorphone 26 (4.9) 21 (7.8)
Hydrocodone 25 (4.7) 18 (6.7)
Oxymorphone 20 (3.7) 15 (5.6)
Codeine +
acetaminophen
8 (1.5) 2 (0.7)
Codeine 0 2 (0.7)
Butalbital + codeine 1 (0.2) 0
Other opioids 77 (14.4) 45 (16.7)
Tramadol 68 (12.7) 41 (15.2)
Tapentadol 7 (1.3) 4 (1.5)
Acetaminophen +
tramadol
3 (0.6) 0
Phenylpiperidine
derivatives
52 (9.7) 26 (9.6)
Fentanyl 50 (9.4) 26 (9.6)
Pethidine 2 (0.4) 0
* Data for rollover patients were summarised as of entry into
the respective pivotal 12-week studies (KODIAC-04 and KODI-
AC-05).
† Use of methadone, partial opioid agonists and opioid ago-
nist/antagonists was prohibited and was recorded as a proto-
col deviation when appropriate. Within each treatment group,
use of methadone, buprenorphine or naloxone + pentazocine
was <1%.
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Adverse events
A majority of patients in each group had a treat-
ment-emergent AE; abdominal pain, diarrhoea, nausea,
headache, ﬂatulence, bronchitis and upper abdominal
pain occurred more frequently with naloxegol than usual
care (Table 4). The incidence of serious AEs (SAEs) was
similar between groups.
Two deaths occurred during the study. One death
occurred in a patient treated with naloxegol; this
individual experienced an SAE of idiopathic generalised
epilepsy 20 days after discontinuation of study drug.
The second death occurred during treatment in a
patient in the usual-care group who had taken
naloxegol 12.5 mg in a previous study. The last dose of
naloxegol was taken at 96 days prior to death. This
patient died in her sleep from an unknown cause on
day 95 of this study. Neither death was considered to
be related to study medication.
Adverse events leading to study discontinuation
Adverse events leading to discontinuation of investiga-
tional product (IP) occurred in 56 (10.5%) patients in
the naloxegol group; the most common associated pre-
ferred terms were diarrhoea (n = 11, 2.1%), abdominal
pain (n = 9, 1.7%) and vomiting (n = 5, 0.9%). By deﬁ-
nition, patients receiving usual care were not adminis-
tered an IP and therefore could not discontinue IP due
to AEs; 5 (1.8%) of patients in this group withdrew from
the study due to AEs.
Treatment-emergent GI AEs
Most GI AEs were mild or moderate in intensity,
occurred in the ﬁrst 12 weeks of treatment, and resolved
during treatment or after discontinuation of treatment.
Abdominal pain was the most commonly reported AE
with naloxegol treatment (Table 4); severity was mild in
53 (9.9%) patients, moderate in 30 (5.6%) and severe in
12 (2.2%) patients. In the usual-care group, severity of
abdominal pain reported as an AE was mild in two
(0.7%) patients, moderate in four (1.5%) and severe in
three (1.1%).
Of the patients treated with naloxegol who reported
abdominal pain, the majority had onset within the ﬁrst
week (59 of 95) and had a total AE duration of ≤14 days
(55 of 95). Onset in the usual-care group varied over the
treatment period, with none starting during the ﬁrst
week of treatment. Abdominal pain was reported as a
SAE by one patient who was treated with naloxegol. The
event occurred on day 19 of treatment, was severe in
intensity and unrelated to study treatment, but resolved
by day 22 of treatment and did not lead to discontinua-
tion. The patient required treatment (not speciﬁed by
the investigator) and subsequently recovered. Nine
patients with abdominal pain discontinued treatment
with naloxegol.
Adverse events of special interest
Adverse events pre-speciﬁed as being of special interest
included selected cardiovascular events (i.e. MACE
events, congestive heart failure), AEs potentially related
to changes in blood pressure or opioid withdrawal, and
GI SAEs adjudicated for bowel perforation.
Adverse events determined by independent adjudica-
tion to meet diagnostic criteria for a MACE event
occurred in two patients in each treatment group,
including the two deaths described previously that
occurred during the study; neither of which were consid-
ered to be related to study medication. Any unexplained
death as per adjudication charter was automatically
Table 4 | Adverse event summary (safety-analysis set)
Adverse event, n (%)*
Naloxegol 25 mg
(n = 534)
Usual care
(n = 270)
Any AE† 437 (81.8) 195 (72.2)
Serious AE 51 (9.6) 30 (11.1)
AE leading to
discontinuation of IP
56 (10.5) NA‡
Death 1 (0.2) 1 (0.4)
Treatment-emergent AEs (≥5% in any treatment group)§
Abdominal pain 95 (17.8) 9 (3.3)
Diarrhoea 69 (12.9) 16 (5.9)
Nausea 50 (9.4) 11 (4.1)
Back pain 48 (9.0) 24 (8.9)
Headache 48 (9.0) 13 (4.8)
Flatulence 37 (6.9) 3 (1.1)
Arthralgia 33 (6.2) 16 (5.9)
Nasopharyngitis 33 (6.2) 15 (5.6)
Upper respiratory
tract infection
31 (5.8) 23 (8.5)
Bronchitis 30 (5.6) 12 (4.4)
Vomiting 27 (5.1) 15 (5.6)
Upper abdominal pain 27 (5.1) 3 (1.1)
Sinusitis 23 (4.3) 19 (7.0)
Urinary tract infection 22 (4.1) 22 (8.1)
AE, adverse event; IP, investigational product; NA, not applica-
ble.
* Percentage data based on the number of patients in the
safety-analysis set in each treatment group and patient group.
† Occurring during either the treatment or post-treatment fol-
low-up periods.
‡ Not assessed because usual care was not considered an IP.
§ Occurring during the treatment period.
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assigned as a MACE event. In addition, one patient in
the usual-care group had an SAE of ischaemic cerebral
infarction on day 74, which was adjudicated as a cere-
brovascular accident. A patient in the naloxegol group
had an SAE of increased troponin on day 156, which
was detected upon admission to hospital for symptoms
of altered consciousness, twitching and confusion. Eleva-
tions of troponin, potassium, creatine phosphokinase
and liver transaminases were noted upon admission;
serial ECG was performed and troponin levels were
monitored. The patient was treated for hyperkalemia,
recovered and was subsequently discharged. The preli-
minary diagnosis was non-ST elevated myocardial infarc-
tion, with a ﬁnal diagnosis of elevated troponin. The
event of elevated troponin was adjudicated as acute myo-
cardial infarction and resulted in discontinuation from
the study. Both events were considered unrelated to
study drug.
The number of patients with AEs related to decreased
blood pressure/orthostatic hypotension was ﬁve (0.9%)
for the naloxegol group and 5 (1.9%) for the usual-care
group; AEs related to increases in blood pressure were
reported in 21 (3.9%) naloxegol-treated patients and 12
(4.4%) patients receiving usual care. Three patients
(0.6%) receiving naloxegol reported an AE of syncope,
and none of the events were considered related to
treatment.
Few GI SAEs were reported [naloxegol, n = 3 (0.6%);
usual care, n = 3 (1.1%)]. No GI SAEs were adjudicated
as bowel perforations.
Adverse events reported as opioid withdrawal AEs
during the treatment period occurred in two patients
taking naloxegol and none in the usual-care arm; both
events were attributed to a change in opioid dose. The
ﬁrst event was reported in a patient receiving twice-daily
administration of morphine 60 mg that was tapered to a
dose of 30 mg. The second event occurred in a patient
at 2 weeks after running out of medication (20 mg oxy-
codone/acetaminophen twice daily). An additional
patient administered naloxegol experienced mild opioid
withdrawal during the follow-up period. The event
occurred 3 days after completion of study medication,
resolved 12 days later and was considered possibly
related to treatment. Most patients did not have a
change from baseline in mHOWS during the study. At
2 h after the ﬁrst dose on day 1, an increase in mHOWS
score of ≥3 was observed in three patients (0.6%) in the
naloxegol group and one patient (0.4%) in the usual-care
group. Twenty-three patients (4.3%) in the naloxegol
group and 10 (3.8%) in the usual-care group recorded a
maximum change from baseline of ≥3 in the mHOWS
score during treatment. Hyperhidrosis was reported in
17 patients (3.2%) treated with naloxegol vs. one patient
(0.4%) in the usual-care group.
Pain scores were similar between patients receiving nal-
oxegol or usual care and were stable throughout the study,
with a mean change from baseline of ≤0.4 for either treat-
ment group. Mean daily opioid doses remained stable
throughout the study (at randomisation to month 1,
months 1 to 3, months 3 to 6, months 6 to 9 and months
9 to 12) for new patients, with a mean change from base-
line ranging from 1.2 to 5.7 MEUs for the naloxegol
group and 2.7 to 5.3 MEUs for the usual-care group;
ﬁndings were similar in rollover patients.
Rescue medication use
During treatment with naloxegol, use of bisacodyl rescue
medication was minimal, with median doses per week of
1.1 mg from randomisation to month 1, and 0 mg from
months 1 to 3, months 3 to 6, months 6 to 9 and
months 9 to 12. Rescue medication was not captured for
the usual-care treatment group, as this was considered
part of the usual-care treatment regimen.
DISCUSSION
In patients with noncancer pain and OIC, naloxegol
25 mg was generally safe and well tolerated over
52 weeks. The overall safety and tolerability data were
consistent with the ﬁndings from the phase 3 pla-
cebo-controlled studies, which were conducted over a
12-week period. The observed AE rate of 81.8% for nal-
oxegol 25 mg in the current study was higher than the
rates observed in the two phase three studies (KODI-
AC-04, 61.2%; KODIAC-05, 69.0%), consistent with a
longer treatment duration.10 Although SAEs for naloxe-
gol 25 mg were lower in the 12-week phase 3 studies
(KODIAC-04, 3.3%; KODIAC-05, 3.4%),10 rates for nal-
oxegol 25 mg vs. usual-care treatment in the current
52-week study were similar (Table 4) and were <3%
across system organ classes. Comparable rates of AEs
leading to discontinuation of naloxegol 25 mg were
observed across the 12-week (10.3% for both KODI-
AC-04 and KODIAC-05)10 and 52-week (Table 4)
studies. In addition, pain scores and mean daily opioid
doses in the naloxegol and usual-care groups were stable
and comparable throughout the study, and there were
no attributable opioid withdrawal AEs observed in either
treatment arm.
Further, no new safety ﬁndings emerged with
continued naloxegol treatment beyond 12 weeks. The
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occurrence of abdominal pain (17.8%), the most fre-
quently reported AE, was comparable to that reported in
the 12-week phase 3 studies (KODIAC-04, 12.6%; KO-
DIAC-05, 19.0%).10 Of particular note are the compara-
ble rates of MACE events and AEs related to blood
pressure changes between usual care and naloxegol. No
events were adjudicated as bowel perforations. In addi-
tion, long-term use of naloxegol was not associated with
signiﬁcant changes in opioid dosing requirements or
pain and withdrawal scores.10
There is little published information on the long-term
safety of peripheral opioid receptor antagonists with con-
tinued administration in the treatment of OIC. Methyl-
naltrexone was examined in a 3-month open-label
extension study of patients with advanced illness and
OIC.15 Methylnaltrexone was administered on an as
needed basis, starting with a dose of 0.15 mg/kg given
subcutaneously and the option to increase the dose to
0.30 mg/kg if a BM failed to occur within 4 h, or to
decrease the dose to 0.075 mg/kg if drug-related AEs
occurred. Apart from AEs related to the medical status
of the patient population, reported AEs were primarily
GI in nature and consisted of abdominal pain (30.5%),
nausea (20.7%), vomiting (19.5%) and ﬂatulence (12.2%).
Similarly, pain scores were unaltered and opioid with-
drawal was not observed as a result of treatment with
methylnaltrexone.
Strengths of this study include the use of a 2-week
period for conﬁrmation of OIC before randomisation,
which ensured that all randomised patients were experi-
encing active OIC at the start of treatment. Also, the
inclusion of an investigator-managed laxative regimen
for patients in the usual-care control group approximates
real-world practice for the management of OIC and
allows for assessment of baseline rates of AEs resulting
from OIC-targeted therapy.
There are several limitations of this study. The open-
label study design allowed patients to know their treat-
ment group assignment and patients were informed of
potential risks with naloxegol treatment during the
informed consent procedure; however, potential risks of
usual-care treatments were not included in informed
consent, thereby introducing a potential confounding
bias in the reporting of AEs and the decision to continue
in the study. Because an investigator-managed laxative
regimen (with a variety of laxative options) was adminis-
tered to patients in the usual-care group, the treatment
regimen would be slightly different for each patient and
would likely impact the type, number and severity of the
individual AEs reported by these patients. In addition,
patients receiving usual care were allowed to change
their treatment rather than having to discontinue the
study for AEs. Thus, it is likely that AEs were underrep-
resented in the usual-care group and overrepresented in
the naloxegol group, as compared to what might be
observed in a real-world clinical setting. Lastly, the
absence of a blinded placebo group does not enable
direct comparison of naloxegol or usual care to no
treatment.
In conclusion, long-term administration of naloxegol
25 mg was generally safe and well tolerated, with preser-
vation of opioid analgesia in patients with noncancer
pain and OIC. The most common AEs observed in the
naloxegol group were GI, as would be expected based on
the underlying mechanism of action at enteric l-opioid
receptors. Treatment with naloxegol is a viable option
for the management of OIC in this patient population
(ClinicalTrials.gov registration: NCT01336205).
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